Clincosm LogoSign in Get a demo

Gastrointestinal Manifestations Among Patients With COVID19

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT04544150
Collaborator
(none)
220
Enrollment
1
Location
3
Actual Duration (Months)
72.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

many patients with confirmed infection with COVID-19 suffer from different symptoms and signs of gastrointestinal symptoms

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    many patients with COVID1-9 infection experienced many intestinal symptoms mainly abdominal pain, vomiting, and diarrhea. This study aimed to assess the frequency of GIT manifestations among patients with COVID-19 and its impact on the outcome

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    220 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Gastrointestinal Manifestations in COVID-19: Symptoms and Signs and Its Impact on the Outcome
    Actual Study Start Date :
    Jun 1, 2020
    Actual Primary Completion Date :
    Sep 1, 2020
    Actual Study Completion Date :
    Sep 1, 2020

    Outcome Measures

    Primary Outcome Measures

    1. frequency of GIT symptoms among patients with COVID-19 infection [Baseline]

      any GIT symptoms in such patients were recorded

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • all patients with COVID19
    Exclusion Criteria:
    • patient refusal to participate in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ahmed Al Minyā Alminya Egypt 71515

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Principal Investigator: Ahmed Abu elfatth, Assuit University Hospitals

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ahmed Mohammed Abu Elfatth, Al-rahji University Hospital, Faculty of Medicine, Assiut, Egypt, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04544150
    Other Study ID Numbers:
    • COVID19 and GUT
    First Posted:
    Sep 10, 2020
    Last Update Posted:
    Sep 10, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Sep 10, 2020